{"id":60118,"date":"2024-02-28T06:34:30","date_gmt":"2024-02-28T06:34:30","guid":{"rendered":"https:\/\/medsname.com\/nootropil\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"nootropil","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/nootropil\/","title":{"rendered":"Nootropil"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Nootropil?<\/h3>\n<p style=\"margin:0;\"><strong>Nootropil<\/strong> este un <strong>comprimat<\/strong> care con\u021bin <strong>piracetam<\/strong> (800 mg) &mdash; the original &#8220;nootropic&#8221; pyrrolidone derivative. Used for: <strong>cortical myoclonus<\/strong> (the FDA\/EMA-evidenced indication), <strong>age-related cognitive decline<\/strong>, <strong>cognitive symptoms after stroke or traumatic brain injury<\/strong>, <strong>vertigo of central origin<\/strong>, \u0219i <strong>dyslexia in children<\/strong> (EU indication, alongside structured remediation). Adult dosing: <strong>2.4&ndash;4.8 g\/day<\/strong> in 2&ndash;3 divided doses (cognitive); 7.2&ndash;24 g\/day for cortical myoclonus. Take with or without food. Onset: 4&ndash;8 weeks for cognitive benefits. Generally well tolerated; common side effects: insomnia, irritability, weight gain, headache. <strong>Contraindicated in severe renal impairment and Huntington&#8217;s disease<\/strong>. Not approved by the US FDA &mdash; sold as a prescription medicine in most of Europe, Asia and Latin America.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">What Is Nootropil?<\/h2>\n<p>Nootropil is an oral piracetam <strong>comprimat<\/strong> available in 800 mg. Piracetam (2-oxo-1-pyrrolidine acetamide) is a cyclic GABA derivative synthesised by UCB in 1964 and the original member of the <strong>racetam class of nootropics<\/strong>. It is licensed in most of Europe, Latin America and Asia as a prescription medicine for <strong>cognitive disorders<\/strong>, <strong>cortical myoclonus<\/strong> \u0219i <strong>vertijului<\/strong>. It is not FDA-approved in the United States but remains widely used internationally.<\/p>\n<p>Nootropil is supplied by a WHO-GMP certified manufacturer and is bioequivalent to originator-brand piracetam (Nootropil&reg;, UCB).<\/p>\n<h2 class=\"wp-block-heading\">How Does Nootropil Work?<\/h2>\n<p>Piracetam&#8217;s mechanism is unusual and incompletely understood after 60 years of clinical use:<\/p>\n<ul>\n<li><strong>Membrane fluidity modulation<\/strong> &mdash; piracetam interacts with phospholipid head-groups, restoring membrane fluidity in aged or damaged neurons. This may underlie its preferential effect in cognitively impaired rather than healthy populations.<\/li>\n<li><strong>Improved cerebral microcirculation<\/strong> &mdash; reduces erythrocyte rigidity and platelet aggregation, modestly improving cerebral blood flow without changing systemic blood pressure.<\/li>\n<li><strong>AMPA receptor modulation<\/strong> &mdash; positive allosteric effect on glutamate AMPA receptors, enhancing long-term potentiation in animal models.<\/li>\n<li><strong>Cholinergic enhancement<\/strong> &mdash; increased high-affinity choline uptake and acetylcholine synthesis in some brain regions.<\/li>\n<li><strong>Mitochondrial protection<\/strong> &mdash; preserves ATP production under hypoxic stress.<\/li>\n<\/ul>\n<p>Unlike sedative anticonvulsants, piracetam has <strong>no GABA-receptor activity, no sedative action, no addiction potential<\/strong> and does not cause cognitive blunting. It is generally inactive in healthy young adults and produces clearer benefit in patients with cognitive impairment, vascular brain disease, or cortical myoclonus.<\/p>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>Cortical myoclonus<\/strong> &mdash; the strongest evidence base; piracetam is a recognised treatment, often as an adjunct to other anticonvulsants<\/li>\n<li><strong>Age-related cognitive impairment<\/strong> &mdash; mild cognitive impairment, vascular cognitive impairment<\/li>\n<li><strong>Post-stroke cognitive recovery<\/strong> &mdash; particularly aphasia after left-hemisphere stroke (EU indication; some RCT support)<\/li>\n<li><strong>Cognitive sequelae of traumatic brain injury<\/strong><\/li>\n<li><strong>Vertigo of central origin<\/strong> &mdash; improves vestibular compensation<\/li>\n<li><strong>Dyslexia in children &gt;7 years<\/strong> &mdash; EU indication, used as an adjunct to structured remediation<\/li>\n<li><strong>Sickle-cell crisis prevention<\/strong> &mdash; off-label, mechanism is the rheological effect on erythrocytes<\/li>\n<li><strong>Off-label:<\/strong> general nootropic \/ cognitive enhancement (limited evidence in healthy young adults)<\/li>\n<\/ul>\n<p>Nootropil is <strong>prime\u0219te,<\/strong> first-line for: Alzheimer&#8217;s dementia (cholinesterase inhibitors and memantine have stronger evidence), depression with cognitive symptoms (treat the depression first), or attention-deficit disorder.<\/p>\n<h2 class=\"wp-block-heading\">Nootropil Dosage and How to Take<\/h2>\n<p>Nootropil strengths: <strong>800 mg<\/strong>.<\/p>\n<p><strong>Doze standard pentru adul\u021bi pe indica\u021bie:<\/strong><\/p>\n<ul>\n<li><strong>Age-related cognitive impairment \/ vascular dementia \/ post-stroke:<\/strong> 2.4&ndash;4.8 g\/day in 2&ndash;3 divided doses. Many patients respond at 2.4 g\/day (e.g. 800 mg three times daily).<\/li>\n<li><strong>Cortical myoclonus:<\/strong> Start 7.2 g\/day in 2&ndash;3 doses. Increase by 4.8 g\/day every 3&ndash;4 days to a maximum of 24 g\/day. Maintenance is the lowest dose that controls myoclonus.<\/li>\n<li><strong>Vertigo:<\/strong> 2.4&ndash;4.8 g\/day in 2&ndash;3 doses for 8&ndash;12 weeks; reassess.<\/li>\n<li><strong>Children with dyslexia (&gt;7 years):<\/strong> 3.2 g\/day in 2 divided doses, alongside structured remedial education.<\/li>\n<li><strong>Afectare renal\u0103:<\/strong> dose-adjust by creatinine clearance &mdash; CrCl 50&ndash;79: standard dose; CrCl 30&ndash;49: half dose; CrCl &lt;30: not recommended.<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\">How to Take Nootropil Properly<\/h3>\n<ol>\n<li><strong>Two to three times a day, evenly spaced.<\/strong> Half-life is 4&ndash;5 hours. Dosing intervals matter for myoclonus; less critical for cognitive use.<\/li>\n<li><strong>Cu sau f\u0103r\u0103 alimente.<\/strong> Food slightly delays absorption but does not reduce the total amount absorbed.<\/li>\n<li><strong>Permite\u021bi 4\u20138 s\u0103pt\u0103m\u00e2ni la doza terapeutic\u0103<\/strong> before judging cognitive benefit. Effects accumulate gradually rather than producing an acute change in mental clarity.<\/li>\n<li><strong>For cortical myoclonus, titrate up over 1&ndash;2 weeks<\/strong> until adequate control. Doses of 16&ndash;24 g\/day are often needed and well tolerated.<\/li>\n<li><strong>Avoid bedtime dosing<\/strong> if you are prone to insomnia &mdash; piracetam can be mildly activating.<\/li>\n<li><strong>Spune\u021bi fiec\u0103rui medic prescriptor.<\/strong> The interaction with thyroid hormone is the only common clinically relevant one.<\/li>\n<li><strong>Stopping is straightforward in most cases &mdash; no specific tapering protocol<\/strong> for cognitive use. For cortical myoclonus, taper under specialist supervision to avoid breakthrough myoclonus.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Side Effects of Nootropil<\/h2>\n<p><strong>Common (often dose-related, often mild):<\/strong><\/p>\n<ul>\n<li>Insomnia, mild agitation<\/li>\n<li>Irritability, hyperkinesia (especially older adults and children)<\/li>\n<li>Dureri de cap<\/li>\n<li>Weight gain (~5% of patients)<\/li>\n<li>Diaree<\/li>\n<li>Drowsiness (paradoxical, less common than insomnia)<\/li>\n<\/ul>\n<p><strong>Mai pu\u021bin frecvente, dar importante:<\/strong><\/p>\n<ul>\n<li>Mood changes, anxiety, depression (rare)<\/li>\n<li>Ame\u021beli<\/li>\n<li>Asthenia<\/li>\n<li>Sexual disturbance (rare)<\/li>\n<li>Increased bleeding tendency &mdash; piracetam mildly inhibits platelet aggregation<\/li>\n<\/ul>\n<p><strong>Rare but seek medical attention:<\/strong><\/p>\n<ul>\n<li>Severe rash or angio-oedema (hypersensitivity)<\/li>\n<li>Worsening of pre-existing Huntington&#8217;s chorea<\/li>\n<li>Severe bleeding events in patients with bleeding disorders or on anticoagulants<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Afectare renal\u0103:<\/strong> piracetam is cleared 100% by the kidneys. Dose-adjust by creatinine clearance; avoid in CrCl &lt;30 mL\/min.<\/li>\n<li><strong>Bleeding tendency:<\/strong> piracetam inhibits platelet aggregation. Caution in patients with peptic ulcer, severe haemorrhage, recent surgery, on anticoagulants or antiplatelets.<\/li>\n<li><strong>Huntington&#8217;s disease:<\/strong> avoid &mdash; piracetam can worsen chorea in some patients.<\/li>\n<li><strong>Older adults:<\/strong> hyperkinesia, agitation and insomnia are more common; start at the lower end of the dose range.<\/li>\n<li><strong>Sarcina:<\/strong> safety not established. Avoid unless benefit clearly outweighs unknown risk &mdash; use only under specialist guidance.<\/li>\n<li><strong>Al\u0103ptarea:<\/strong> piracetam is excreted in breast milk; avoid or stop breastfeeding.<\/li>\n<li><strong>Elective surgery:<\/strong> stop piracetam 1 week before surgery if practical, because of the platelet effect.<\/li>\n<li><strong>Conducere:<\/strong> drowsiness occasionally occurs; do not drive until you know how the drug affects you.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindications &mdash; Who Should NOT Take Nootropil<\/h2>\n<ul>\n<li>Known hypersensitivity to piracetam, pyrrolidone derivatives, or any excipient<\/li>\n<li>End-stage renal impairment (CrCl &lt;20 mL\/min)<\/li>\n<li>Cerebral haemorrhage (acute)<\/li>\n<li>Huntington&#8217;s disease<\/li>\n<li>Pregnancy and breastfeeding (unless specialist judges benefit outweighs risk)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Thyroid hormone (thyroxine, T3)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Case reports of confusion, tremor and sleep disturbance<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Use with caution; observe for adrenergic-like symptoms.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin or other anticoagulants<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive bleeding tendency (piracetam mildly inhibits platelets)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitor INR or bleeding; piracetam alone does not prolong INR but may worsen bleeding from anticoagulants.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aspirin, NSAIDs, antiplatelets<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive antiplatelet effect<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Caution; avoid combination in patients with bleeding history.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Alcool<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No significant pharmacokinetic interaction; minimal additive CNS effects<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Generally safe in moderation.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Other AMPA-modulating agents<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Theoretical additive effects<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Supraveghere specializat\u0103.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Carbamazepine, phenytoin, sodium valproate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Nicio interac\u021biune semnificativ\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Used together for myoclonic syndromes.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Instruc\u021biuni de Depozitare<\/h2>\n<ul>\n<li>Se p\u0103streaz\u0103 la temperatura camerei, <strong>15\u201330\u00b0C<\/strong>. Proteja\u021bi de umiditate.<\/li>\n<li>P\u0103stra\u021bi comprimatele \u00een ambalajul original blister p\u00e2n\u0103 la utilizare.<\/li>\n<li>Nu depozita\u021bi \u00een baie.<\/li>\n<li>P\u0103stra\u021bi la distan\u021b\u0103 de copii.<\/li>\n<li>Nu utiliza\u021bi dup\u0103 data de expirare.<\/li>\n<li>Return unused medication to a pharmacy for proper disposal.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente disponibile pentru afec\u021biuni conexe:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/neurological-conditions-and-epilepsy\/\">R\u0103sfoi\u021bi toate medicamentele neurologice \u0219i antiepileptice<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/anti-migraine\/\">R\u0103sfoi\u021bi medicamentele anti-migren\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/mental-health-and-psychiatric-medications\/\">R\u0103sfoi\u021bi medicamentele pentru s\u0103n\u0103tatea mintal\u0103 \u0219i psihiatrie<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">How long does Nootropil take to work?<\/h3>\n<p><strong>Cognitive benefits accumulate gradually over 4&ndash;8 weeks<\/strong> at therapeutic dose &mdash; this is not a drug that produces an acute lift in mental clarity within hours. For <strong>cortical myoclonus<\/strong>, response can be seen within 1&ndash;2 weeks once the dose reaches the therapeutic range (typically 7.2&ndash;24 g\/day). For <strong>post-stroke aphasia<\/strong>, benefit develops over 6&ndash;12 weeks alongside speech therapy. If there is no detectable benefit at 8 weeks, dose escalation or alternative therapy is appropriate.<\/p>\n<h3 class=\"wp-block-heading\">Why is Nootropil not FDA-approved in the US?<\/h3>\n<p>Piracetam was developed in Belgium in the 1960s and has been licensed across Europe, Asia and Latin America for decades. The originator never sought FDA approval in the United States &mdash; partly because the development costs would not have been recouped given that piracetam came off patent before the modern FDA approval pathway matured, and partly because trial endpoints for cognitive enhancement were not well defined at the time. The drug remains a recognised pharmaceutical with substantial long-term safety data in the markets where it is licensed.<\/p>\n<h3 class=\"wp-block-heading\">Is Nootropil a true &#8220;nootropic&#8221;?<\/h3>\n<p><strong>Piracetam is the original drug for which the term &#8220;nootropic&#8221; was coined<\/strong> by its co-discoverer Corneliu Giurgea in 1972. The original definition required: enhancement of learning\/memory, protection against impairment, very low toxicity, no sedation or stimulation, and absence of typical pharmacological side effects. Piracetam fits this definition. In contemporary use the term &#8220;nootropic&#8221; has been applied to many supplements without comparable evidence; piracetam remains in a separate category as a regulated prescription medicine.<\/p>\n<h3 class=\"wp-block-heading\">Will Nootropil work for healthy young adults wanting cognitive enhancement?<\/h3>\n<p><strong>The evidence is weakest in this group.<\/strong> Most clinical trials are in older adults, post-stroke patients or patients with cognitive impairment &mdash; populations where piracetam shows clearer benefit. In healthy young adults, controlled studies are scarce and the effect, if any, is modest. Piracetam is not a substitute for sleep, exercise, hydration, or stimulant medication when those are appropriate.<\/p>\n<h3 class=\"wp-block-heading\">What is the difference between piracetam and other racetams?<\/h3>\n<p><strong>Piracetam<\/strong> is the original racetam &mdash; lowest potency, most evidence, longest safety record. <strong>Aniracetam<\/strong> is fat-soluble, faster-acting, slightly more anxiolytic; <strong>oxiracetam<\/strong> is more stimulating; <strong>levetiracetam<\/strong> is a structurally related anticonvulsant with very different pharmacology and FDA approval; <strong>brivaracetam<\/strong> is a newer focal-seizure anticonvulsant. Of these, only piracetam and levetiracetam have substantial human clinical evidence; the others are mostly used off-label or as supplements.<\/p>\n<h3 class=\"wp-block-heading\">Does Nootropil interact with my thyroid medication?<\/h3>\n<p><strong>There are case reports<\/strong> of confusion, tremor, and sleep disturbance when piracetam is combined with thyroxine or T3, suggesting a possible adrenergic-style interaction. The mechanism is not understood. If you are on thyroid hormone replacement, tell your prescriber before starting piracetam, observe for tremor, anxiety or sleep disturbance, and lower the piracetam dose if symptoms occur.<\/p>\n<h3 class=\"wp-block-heading\">Does Nootropil cause weight gain?<\/h3>\n<p><strong>Mild weight gain is reported in about 5% of patients<\/strong>, more often in older adults and at higher doses (8 g\/day or more). The mechanism is not clearly understood. The effect is reversible on dose reduction or discontinuation.<\/p>\n<h3 class=\"wp-block-heading\">Can Nootropil be used in children?<\/h3>\n<p><strong>Yes &mdash; piracetam is licensed in Europe for dyslexia in children &gt;7 years<\/strong> as an adjunct to structured remedial education. Typical dose is 3.2 g\/day in 2 divided doses. It is also used in paediatric cortical myoclonus and post-traumatic cognitive sequelae. Hyperkinesia and irritability are slightly more common in children; close parental observation is reasonable.<\/p>\n<h3 class=\"wp-block-heading\">Is Nootropil addictive?<\/h3>\n<p><strong>Nu.<\/strong> Piracetam has no GABA receptor activity, no opioid activity, no stimulant action and no documented potential for tolerance or addiction. It can be stopped without a structured taper for cognitive indications, although for cortical myoclonus a gradual reduction is sensible to avoid breakthrough symptoms.<\/p>\n<h3 class=\"wp-block-heading\">Can I drink alcohol on Nootropil?<\/h3>\n<p><strong>Yes, in moderation.<\/strong> There is no specific pharmacokinetic interaction and no documented additive risk. Heavy drinking remains harmful to cognition independently. Some patients use piracetam off-label after acute intoxication on the theory that it improves recovery; the evidence for that use is limited.<\/p>\n<h3 class=\"wp-block-heading\">Where is Nootropil manufactured?<\/h3>\n<p>Nootropil is supplied by a <strong>produc\u0103tor certificat WHO-GMP<\/strong> and is bioequivalent to originator-brand piracetam (Nootropil&reg;, UCB) at the same milligram strength. Batch certificates of analysis are available on request.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cerecetam\/\">Cerecetam<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ramcor\/\">Ramcor<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/teravir\/\">Teravir<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/efavir\/\">Efavir<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/elocon-cream\/\">Elocon Cream<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u00cembun\u0103t\u0103\u021be\u0219te func\u021bia cognitiv\u0103<br \/>\n\u2705 Improves memory retention<br \/>\n\u2705 Spore\u0219te claritatea mintal\u0103<br \/>\n\u2705 Increases focus and alertness<br \/>\n\u2705 Sus\u021bine s\u0103n\u0103tatea creierului<\/p>\n<p>Nootropil contains Piracetam.<\/p>","protected":false},"featured_media":60119,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3468],"product_tag":[4813,4800],"class_list":{"0":"post-60118","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-neurological-conditions-and-epilepsy","9":"product_tag-nootropil","10":"product_tag-piracetam","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60118"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60119"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60118"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60118"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60118"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}